4.7 Review

Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan

期刊

JOURNAL OF GASTROENTEROLOGY
卷 48, 期 1, 页码 31-72

出版社

SPRINGER JAPAN KK
DOI: 10.1007/s00535-012-0673-1

关键词

Crohn's disease; Guidelines; Practice guidelines; Evidence; Consensus

资金

  1. Ministry of Health, Labour and Welfare of Japan
  2. Eisai Co., Ltd.
  3. Mitsubishi Tanabe Pharma Co.
  4. Ajinomoto Pharmaceuticals Co., Ltd.
  5. Zeria Pharmaceutical Co., Ltd.
  6. Kyorin Pharmaceutical Co., Ltd.
  7. JIMRO Co., Ltd.
  8. Astellas Pharma Inc.
  9. ABBOTT JAPAN Co., Ltd.
  10. ABBOTT JAPAN Co., Ltd
  11. Asahi Kasei Kuraray Medical Co., Ltd
  12. AstraZeneca
  13. Chugai Pharmaceutical Co., Ltd
  14. DAIICHI SANKYO CO., Ltd.
  15. Kyowa Hakko Kirin Co., Ltd
  16. Kyorin Pharmaceutical Co. Ltd
  17. JIMRO Co., Ltd
  18. MSD K.K.
  19. Otsuka Pharma Co., Ltd
  20. UCB Japan Co., Ltd
  21. Zeria Pharmaceutical Co., Ltd
  22. Takeda Pharmaceutical Co., Ltd.
  23. Asahi Kasei Kuraray Medical Co., Ltd.

向作者/读者索取更多资源

Crohn's disease is a disorder of unknown etiology and complicated pathogenesis. A substantial amount of evidence has accumulated recently and has been applied to clinical practice. The present guidelines were developed based on recent evidence and the formal consensus of experts relevant to this disease. Here we provide an overview of these guidelines, as follows. Target disease: Crohn's disease Users: Clinical practitioners in internal medicine, surgery, gastroenterology, and general practice Purpose: To provide appropriate clinical indicators to practitioners Scope of clinical indicators: Concept of Crohn's disease, epidemiology, classifications, diagnosis, treatment, follow up, and special situations Intervention: Diagnosis (interview, physical examination, clinical laboratory tests, imaging, and pathology) and treatment (lifestyle guidance, drug therapy, nutritional therapy, surgery, etc.) Outcome assessment: Attenuation of symptoms, induction and maintenance of remission, imaging findings, quality of life (QOL), prevention of complications and harm of therapy Methods for developing these guidelines: Described in the text Basis of recommendations: Integration of evidence level and consensus of experts Cost-benefit analysis: Not implemented Evaluation of effectiveness: Yet to be confirmed Status of guidelines: Updated version of the first Guidelines published in 2010 Publication sources: Printed publication available and electronic information in preparation Patient information: Not available Date of publication: October 2011 These guidelines were intended primarily to be used by practitioners in Japan, and the goal of these guidelines is to improve the outcomes of patients with Crohn's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据